| NCT ID | Title | Status | Phases | Start Date | Completion Date | Primary Completion Date |
|---|---|---|---|---|---|---|
| NCT05256290 | Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2022-03-31 | 2026-06 | 2025-07 |
| NCT04209465 | A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors. | TERMINATED | PHASE1 | 2019-12-19 | 2022-09-16 | 2022-09-02 |